INS068 clinical trials
How each study uses INS068 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- INS068 injection
- 4
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses INS068 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.CompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05702073Written as INS068 injection
- To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic DrugsCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05699408Written as INS068 injection
- The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05336071Written as INS068 injection
- A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral AntidiabeticsCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT04663282Written as INS068 injection